由于暴露前后的疫苗接种是预防狂犬病的唯一有效措施，而目前国内所用的浓缩狂犬病疫苗其保护性、副反应性等仍亟需改进，研制纯化疫苗以替代浓缩疫苗已成为当务之急。国家药管局对此非常重视，已将纯化狂犬病疫苗列为国家二类新药。目前国内已有十多家科研生产单位向国家新药审评中心申报了纯化狂犬病疫苗的新药申请，本文根据危险人群狂犬病发病及疫苗使用现状，就纯化狂犬病疫苗及其方法的研究进展作一综述。 Vaccination before and after exposure is the only effective measure to prevent rabies. However, the protection and side-reactivity of the concentrated rabies vaccine currently used in China are still in urgent need of improvement. Therefore, the development of a purified vaccine instead of a concentrated vaccine has become a top priority. National Drug Authority attaches great importance to this, the purified rabies vaccine has been classified as two types of national new drugs. At present, there are more than ten scientific research and production units in China applying for the application of the new drug for purifying rabies vaccine to the National Center for Drug Evaluation. In this paper, the research progress of rabies vaccine and its purification methods are reviewed in this paper according to the incidence of rabies and the current status of the vaccine in the dangerous population.